Who is sponsoring NCT05485272?

NCT05485272 is sponsored by Cairo University.

What drugs are being tested in NCT05485272?

Interventions in NCT05485272: Silver Diamine Fluoride combined with Potassium Iodide., Silver Diamine Fluoride., High-Viscosity Glass Ionomer..

What condition does NCT05485272 study?

NCT05485272 studies Carious Lesion.

Is NCT05485272 still recruiting?

NCT05485272 is currently status unknown. Last updated 3 August 2022.

Last reviewed 2022-08-03 · How we verify

NCT05485272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of SDF Combined With KI Versus SDF in Management of Class I Carious Lesions

Status unknown NA Last updated 3 August 2022

What this trial tests

NA trial testing Silver Diamine Fluoride combined with Potassium Iodide. in Carious Lesion in 42 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
10 September 2022

2 March 2023

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	42
Start date	1 February 2022
Primary completion	10 September 2022
Estimated completion	2 March 2023
Sites	1 location across Egypt

Drugs / interventions tested

Silver Diamine Fluoride combined with Potassium Iodide.
Silver Diamine Fluoride.
High-Viscosity Glass Ionomer.

Conditions studied

Carious Lesion — all drugs for Carious Lesion →

Sponsor

Cairo University

Who can join

Adults 18 to 40, any sex, with Carious Lesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the clinical performance of High-Viscosity Glass Ionomer (EQUIA) versus Silver Diamine Fluoride combined with Potassium Iodide (Riva Star) and Sliver Diamine Fluoride (SDF) under High-Viscosity Glass Ionomer (EQUIA) in deep class I carious lesions, over a period of one year follow-up. The null hypothesis tested in this study, that in deep class I carious lesions, the High-Viscosity Glass Ionomer (EQUIA) versus Silver Diamine Fluoride combined with Potassium Iodide (Riva Star) and Sliver Diamine Fluoride (SDF) under High-Viscosity Glass Ionomer (EQUIA) will show the same clinical performance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05485272 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 3 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05485272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing